The Food and Drug Administration awarded the drug’s sponsor, biotech company Revolution Medicines, a new and unconventional ...
New diagnostic kits aim to revolutionize early screening of the disease, potentially allowing patients to receive treatments—such as monoclonal antibodies—sooner.
Developers of biosimilars will no longer be required to conduct clinical trials to prove effectiveness for FDA approval.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback